CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To the best of our knowledge, we hereby report for the first time the results of a wide transcriptome analysis of BM CD34+/lin- cells of 78 CP-CML patients at diagnosis vs. 12 months of nilotinib treatment.